Cramer Pamela J. 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Cramer Pamela J.
Chief Human Resources Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-07$19.02/sh+8,805$167,471→ 29,619 total - Sale
Common Stock
2025-11-10$100.00/sh−3,515$351,500→ 20,814 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-11-07−8,805→ 5,257 totalExercise: $19.02Exp: 2031-07-25→ Common Stock (8,805 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2025-11-10−3,515→ 3,520 totalExercise: $6.80Exp: 2032-02-08→ Common Stock (3,515 underlying) - Exercise/Conversion
Common Stock
2025-11-07$6.80/sh+10,546$71,713→ 40,165 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-11-07−10,546→ 7,035 totalExercise: $6.80Exp: 2032-02-08→ Common Stock (10,546 underlying) - Sale
Common Stock
2025-11-07$98.82/sh−19,351$1,912,326→ 20,814 total - Exercise/Conversion
Common Stock
2025-11-10$6.80/sh+3,515$23,902→ 24,329 total
Footnotes (3)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.
- [F2]The stock option is fully vested.
- [F3]The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.